Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Rua da Junqueira 126, 1349-019 Lisbon, Portugal.
Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Rua da Junqueira 126, 1349-019 Lisbon, Portugal; CEDOC Chronic Diseases Research Centre, Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.
Clin Neurol Neurosurg. 2021 Sep;208:106829. doi: 10.1016/j.clineuro.2021.106829. Epub 2021 Jul 21.
Point mutations in the Peripheral Myelin Protein 22 (PMP22) gene comprise less than 5% of the Charcot-Marie-Tooth (CMT) type 1 cases, and individualize either the CMT 1E subtype, or Hereditary Neuropathy with Liability to Pressure Palsy. The phenotype of CMT 1E presents with a severe early-onset polyneuropathy associated with deafness, although the clinical spectrum is broad.
We describe a novel PMP22 gene point mutation (c.84G>T;p.(Trp28Cys)) in three patients of a Portuguese family with variable phenotypes, ranging from asymptomatic to mild complaints of distal limb numbness and gait difficulties, with the age of onset of symptoms ranging from mid-twenties to late-sixties, and no associated disability. In all affected patients, there was evidence of diffuse demyelinating sensorimotor polyneuropathy. Hearing loss does not seem to be associated with this variant, albeit neuropathic pain was reported.
These findings suggest that this particular point mutation in the PMP22 gene is associated with a mild phenotype, further emphasizing that there are still unknown mechanisms (genetic and/or epigenetic) that may play a role in the clinical spectrum of CMT1E patients. Next generation sequencing panels including commonly mutated genes in CMT should be considered in CMT1 cases negative for PMP22 gene duplication.
在外周髓髓鞘蛋白 22(PMP22)基因中的点突变占 1 型遗传性运动感觉神经病(CMT1)病例的不到 5%,可分别确定 CMT1E 亚型或遗传性压力易感性神经病。CMT1E 的表型表现为严重的早发性多发性神经病伴耳聋,尽管临床表现广泛。
我们描述了葡萄牙一个家系的 3 名患者中存在一种新的 PMP22 基因突变(c.84G>T;p.(Trp28Cys)),其表型各不相同,从无症状到四肢远端麻木和行走困难的轻度症状,症状起始年龄从二十多岁到六十多岁不等,且无相关残疾。所有受影响的患者均有弥漫性脱髓鞘感觉运动性多发性神经病的证据。尽管有报道称存在神经病理性疼痛,但听力损失似乎与该变体无关。
这些发现表明,PMP22 基因中的这种特定点突变与轻度表型相关,进一步强调了仍有未知的机制(遗传和/或表观遗传)可能在 CMT1E 患者的临床表现中起作用。在 PMP22 基因重复阴性的 CMT1 病例中,应考虑包含 CMT 常见突变基因的下一代测序组。